Literature DB >> 23397985

YKL-40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis.

Yasutomo Imai, Seiko Aochi, Keiji Iwatsuki, Hajime Sano, Kiyofumi Yamanishi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23397985     DOI： 10.1111/1346-8138.12061

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  2 in total

Review 1.  The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review.

Authors:  Kalthoum Tizaoui; Jae Won Yang; Keum Hwa Lee; Ji Hong Kim; Minseok Kim; Sojung Yoon; Yeonwoo Jung; Joon Beom Park; Kitae An; Hyeok Choi; Donggyu Song; HyunTaek Jung; Seongmin Ahn; Taeho Yuh; Hee Min Choi; Jae Ha Ahn; Younjuong Kim; Sanghyun Jee; Hyeongsun Lee; Soohwa Jin; Jun-Gu Kang; Bohyun Koo; Joo Yeop Lee; Kyoung Min Min; Wonseok Yoo; Hyeong Jun Rhyu; Yeonjung Yoon; Min Ho Lee; Sung Eun Kim; Jimin Hwang; Ai Koyanagi; Louis Jacob; Seoyeon Park; Jae Il Shin; Lee Smith
Journal:  Int J Biol Sci       Date:  2022-05-21       Impact factor: 10.750

2.  Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis.

Authors:  Joanna Salomon; Łukasz Matusiak; Danuta Nowicka-Suszko; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2017-08-28       Impact factor: 4.711
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.